Publications by authors named "Kalgi Mody"

Claim this Profile
T
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Kalgi Mody

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parental Perspectives From the Survey of Sleep Quality in the PICU Validation Study on Environmental Factors Causing Sleep Disruption in Critically Ill Children.
Amanda B Hassinger, Kalgi Mody, Simon Li, Lauren K Flagg, E Vincent S Faustino

Crit Care Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT.
Richard S Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J Knox, Kalgi Mody

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Survey of Sleep Quality in the Pediatric Intensive Care Unit (SSqPICU).
Amanda B Hassinger, Kalgi Mody, Raquel Gomez, Brian H Wrotniak, Kim Falkowski

J Clin Sleep Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
Masatoshi Kudo, Richard S Finn, Masafumi Ikeda, Max W Sung, Ari D Baron, Kalgi Mody

Liver Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Fabio Piscaglia, Kenji Ikeda, Ann-Lii Cheng, Masatoshi Kudo, Masafumi Ikeda, Kalgi Mody

Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Josep M Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Kalgi Mody

Lancet Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Kalgi Mody

Lancet Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Kalgi Mody

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Josep M Llovet, Arndt Vogel, David C Madoff, Richard S Finn, Sadahisa Ogasawara, Kalgi Mody

Cardiovasc Intervent Radiol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Kalgi Mody

Lancet Gastroenterol Hepatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard Finn, Shukui Qin, Kalgi Mody

J Gastroenterol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Kalgi Mody

N Engl J Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Kalgi Mody

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Kalgi Mody

Future Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More Than Skin Deep: Lethargy and Diaphoresis in the Morning.
Robert A Finkelstein, Kalgi Mody, Chani Traube, Francine Blei

Pediatr Emerg Care· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzodiazepines and Development of Delirium in Critically Ill Children: Estimating the Causal Effect.
Kalgi Mody, Savneet Kaur, Elizabeth A Mauer, Linda M Gerber, Bruce M Greenwald

Crit Care Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis